These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 29452143)

  • 61. Vaccination of koalas (Phascolarctos cinereus) against Chlamydia pecorum using synthetic peptides derived from the major outer membrane protein.
    Nyari S; Khan SA; Rawlinson G; Waugh CA; Potter A; Gerdts V; Timms P
    PLoS One; 2018; 13(6):e0200112. PubMed ID: 29953523
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Dendritic cells (DCs) transfected with a recombinant adenovirus carrying chlamydial major outer membrane protein antigen elicit protective immune responses against genital tract challenge infection.
    Lü H; Wang H; Zhao HM; Zhao L; Chen Q; Qi M; Liu J; Yu H; Yu XP; Yang X; Zhao WM
    Biochem Cell Biol; 2010 Aug; 88(4):757-65. PubMed ID: 20651849
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Immunogenicity of multi-epitopes gene of major outer membrane protein of Chlamydia trachomatis].
    Zhu SL; Shi ZH; Li WS; Chen J; Zhang LF
    Zhonghua Yu Fang Yi Xue Za Zhi; 2009 Mar; 43(3):232-6. PubMed ID: 19534931
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Comparison of the nine polymorphic membrane proteins of Chlamydia trachomatis for their ability to induce protective immune responses in mice against a C. muridarum challenge.
    Pal S; Favaroni A; Tifrea DF; Hanisch PT; Luczak SET; Hegemann JH; de la Maza LM
    Vaccine; 2017 May; 35(19):2543-2549. PubMed ID: 28385608
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Towards a Chlamydia trachomatis vaccine: how close are we?
    Cochrane M; Armitage CW; O'Meara CP; Beagley KW
    Future Microbiol; 2010 Dec; 5(12):1833-56. PubMed ID: 21155665
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Biodegradable PLGA85/15 nanoparticles as a delivery vehicle for Chlamydia trachomatis recombinant MOMP-187 peptide.
    Taha MA; Singh SR; Dennis VA
    Nanotechnology; 2012 Aug; 23(32):325101. PubMed ID: 22824940
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Protection Against Chlamydia trachomatis Infection and Upper Genital Tract Pathological Changes by Vaccine-Promoted Neutralizing Antibodies Directed to the VD4 of the Major Outer Membrane Protein.
    Olsen AW; Follmann F; Erneholm K; Rosenkrands I; Andersen P
    J Infect Dis; 2015 Sep; 212(6):978-89. PubMed ID: 25748320
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The Chlamydia trachomatis PmpD adhesin forms higher order structures through disulphide-mediated covalent interactions.
    Paes W; Dowle A; Coldwell J; Leech A; Ganderton T; Brzozowski A
    PLoS One; 2018; 13(6):e0198662. PubMed ID: 29912892
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Exploiting antigenic diversity for vaccine design: the chlamydia ArtJ paradigm.
    Soriani M; Petit P; Grifantini R; Petracca R; Gancitano G; Frigimelica E; Nardelli F; Garcia C; Spinelli S; Scarabelli G; Fiorucci S; Affentranger R; Ferrer-Navarro M; Zacharias M; Colombo G; Vuillard L; Daura X; Grandi G
    J Biol Chem; 2010 Sep; 285(39):30126-38. PubMed ID: 20592031
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Advances in
    Kiekens C; Morré SA; Vanrompay D
    Microorganisms; 2024 Jun; 12(6):. PubMed ID: 38930578
    [No Abstract]   [Full Text] [Related]  

  • 71. Viral Vector-Based
    Andreacchio G; Longo Y; Moreno Mascaraque S; Anandasothy K; Tofan S; Özün E; Wilschrey L; Ptok J; Huynh DT; Luirink J; Drexler I
    Vaccines (Basel); 2024 Aug; 12(8):. PubMed ID: 39204067
    [No Abstract]   [Full Text] [Related]  

  • 72. A Chlamydia trachomatis VD1-MOMP vaccine elicits cross-neutralizing and protective antibodies against C/C-related complex serovars.
    Olsen AW; Rosenkrands I; Holland MJ; Andersen P; Follmann F
    NPJ Vaccines; 2021 Apr; 6(1):58. PubMed ID: 33875654
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Super-Resolution Fluorescence Microscopy Reveals Clustering Behaviour of
    Danson AE; McStea A; Wang L; Pollitt AY; Martin-Fernandez ML; Moraes I; Walsh MA; MacIntyre S; Watson KA
    Biology (Basel); 2020 Oct; 9(10):. PubMed ID: 33092039
    [No Abstract]   [Full Text] [Related]  

  • 74. Fluorescent in situ folding control for rapid optimization of cell-free membrane protein synthesis.
    Müller-Lucks A; Bock S; Wu B; Beitz E
    PLoS One; 2012; 7(7):e42186. PubMed ID: 22848743
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Oral Chlamydia vaccination induces transmucosal protection in the airway.
    Zhu C; Lin H; Tang L; Chen J; Wu Y; Zhong G
    Vaccine; 2018 Apr; 36(16):2061-2068. PubMed ID: 29550196
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Human antibody signatures towards the Chlamydia trachomatis major outer membrane protein after natural infection and vaccination.
    Rosenkrands I; Olsen AW; Knudsen S; Dehari N; Juel HB; Cheeseman HM; Andersen P; Shattock RJ; Follmann F
    EBioMedicine; 2024 Jun; 104():105140. PubMed ID: 38744110
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Immune signature of Chlamydia vaccine CTH522/CAF®01 translates from mouse-to-human and induces durable protection in mice.
    Olsen AW; Rosenkrands I; Jacobsen CS; Cheeseman HM; Kristiansen MP; Dietrich J; Shattock RJ; Follmann F
    Nat Commun; 2024 Feb; 15(1):1665. PubMed ID: 38396019
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Sublingual Boosting with a Novel Mucoadhesive Thermogelling Hydrogel Following Parenteral CAF01 Priming as a Strategy Against Chlamydia trachomatis.
    Garcia-Del Rio L; Diaz-Rodriguez P; Pedersen GK; Christensen D; Landin M
    Adv Healthc Mater; 2022 Jun; 11(11):e2102508. PubMed ID: 35124896
    [TBL] [Abstract][Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.